Cargando…
Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics
Patent pools for second and third-line Fixed Dose Combination (FDC) antiretroviral drugs (ARVs) should not be delayed as they are instrumental to urgent public health needs in the under-served markets. Nonetheless, multinational originator companies still seem to perceive patent pooling for ARVs as...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Open
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831190/ https://www.ncbi.nlm.nih.gov/pubmed/20200604 http://dx.doi.org/10.2174/1874613601004020070 |